Options
Unexpected Rapid Progression of Metastatic Adenoid Cystic Carcinoma during Treatment with Imatinib Mesylate
Resource
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK v.27 n.12 pp.1022 - 1027
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Journal Volume
v.27
Journal Issue
1027
Pages
-
Date Issued
2005
Date
2005
Author(s)
YEN, RUOH-FANG
JENG, YUNG-MING
TZEN, KAI-YUAN
HSU, CHIUN
HONG, RUEY-LONG
Abstract
Background. There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate , a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC. Methods. Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed. Results. Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c- kit and PDGFR-alpha.
Subjects
adenoid cystic carcinoma
imatinib mesylate
KIT
PDGFR